hotspot -WSS

hotspot

author：hotspot 2025-09-29 22:38:13 - browse：27183

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Marc Tessier

focus

WSS

Trump allegedly attempted to have surveillance video deleted: Special Counsel

CDC backtracks, saying fully vaccinated people can go maskless indoors

Biden announces an advanced cancer research initiative

HIPAA doesn't protect reproductive records from prosecutors

FDA official pushes for dedicated emerging pathogens team

Caitlin Bernard's story shows physicians can't shy from advocacy

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Ford recalls 870K F

The cancer drug shortage isn’t new — and neither are the solutions

Elizabeth Warren probes abortion access

At least 13 dead in Texas as scorching temps continue

As Taiwan prepares for anti

Supreme Court strikes down use of affirmative action

Our daughter's deadly disease: trisomy 18. We wanted to protect her

As demand for Covid shots wanes, Moderna seeks its next success

AbbVie dramatically boosts its spending on lobbying

explore

As the dark side of IVF slowly comes into focus, even more transparency is needed

FDA official pushes for dedicated emerging pathogens team

Will.i.am, Britney Spears release new single, 'Mind Your Business'

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

As the dark side of IVF slowly comes into focus, even more transparency is needed

Stoke drug shows lower activity against childhood epilepsy

knowledge

focus

Wikipedia

focus